
医渡科技 1 月通讯 | 2023 年

Yidu Tech Events in January 2023

集团亮点

Business Update

医渡科技升级调整组织架构，徐济铭担任集团首席执行官

Yidu Tech upgrades and restructures its organization, with Xu Jiming as Group Chief Executive Officer

医渡科技宣布组织架构升级调整，在坚持战略聚焦的同时，公司通过加强组织领导机制设计，增强商业系统组织的战斗力，进一步向商业生态的可持续健康发展倾斜力量与资源，扎实构建医疗智能产业新生态，以更好地实现“绿色医疗”这一长期目标。徐济铭担任集团首席执行官兼执行董事，封晓瑛担任集团首席财务官兼执行董事。

Yidu Tech announced the upgrade of its organizational structure. While adhering to its strategic focus, the company has strengthened its organizational leadership mechanism design, improved the commercial system structure, further tilted its strength and resources towards the sustainable and healthy development of the commercial ecology, and solidly built a new ecology of healthcare intelligence industry in order to better realize the long-term goal of "Green Healthcare". Mr. Xu Jiming serves as the Group's Chief Executive Officer and Executive Director, and Ms. Feng Xiaoying serves as the Group's Chief Financial Officer and Executive Director.

徐济铭表示，医渡科技将坚持研发创新，并推动集团战略聚焦，加强跨团队、跨业务的联动，进一步提升集团运营效率，实现业务及各项经营指标的稳步提升。

Mr. Xu Jiming said that Yidu Tech will persist in R&D innovation, promote the Group's strategic focus, strengthen cross-team and cross-business linkages to further enhance the Group's operational efficiency and achieve a steady improvement in business and various operational indicators.

医渡科技收到多封来自全国各地的感谢信

Yidu Tech receives several letters of thanks from all over the country

年末岁初，医渡科技收到中山大学附属肿瘤医院、中国科学院大学附属肿瘤医院浙江省肿瘤医院、新疆医科大学附属肿瘤医院、阿斯利康投资（中国）有限公司、基石药业（苏州）有限公司等多封来自全国各地的感谢信、表扬信。来信对医渡科技的产品、技术实力，以及过去一年里项目组成员的专业和辛勤付出，给予充分肯定。

At the turn of the year, Yidu Tech received many letters of appreciation and commendation from all over the country, including the Cancer Hospital of Sun Yat-sen University, Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital, the Cancer Hospital of Xinjiang Medical University, AstraZeneca Investment (China) Limited and Keystone Pharmaceutical (Suzhou) Co. These letters fully affirmed the products and technical strength of Yidu Tech, as well as the professionalism and hard work of the project team members in the past year.

医渡科技举办中医药研发数字化创新论坛，数据智能助力中医药研发跑出加速度

Yidu Tech held a forum on digital innovation in TCM R&D, data intelligence helped TCM R&D to run at an accelerated pace

多位中医药领域专家、创新药企研发负责人、数字化专家出席会议，研讨以远程智能临床试验为代表的数字化技术和真实世界研究在中医药研发领域的实践路径，推动中医药传承创新发展。

A number of experts in the field of TCM, R&D heads of innovative pharmaceutical companies and digitalization experts attended the conference to discuss the practical path of digital technology represented by remote intelligent clinical trials and real-world research in the field of TCM R&D, and promote the inheritance, innovation and development of TCM.

Happy Life Tech

中医药研发数字化创新论坛

研讨主题：中医药临床研究数字化应用的机遇和挑战

研讨会



研讨主持人
李高扬 博士
开心生活科技远程智能临床试验负责人，副总裁



讨论嘉宾
元维安 博士
上海中医药大学附属曙光医院临床研究中心主任、GCP中心主任



讨论嘉宾
张丽娜
贵阳天药业股份有限公司 处方药妇科医学总监



讨论嘉宾
刘建平 博士
北京中医药大学国际循证医学研究院执行院长，循证医学中心主任



讨论嘉宾
周君
安徽济人药业研发总监



讨论嘉宾
李捷坤
北京中医药大学东直门医院国家药物临床试验机构办公室主任

王会娟



李瑞峰-北京中医药大学附属医院



齐人药业-杨攀





Happy Life Tech

中医药研发数字化创新论坛

研讨主题：中医药真实世界研究的实践与思考

研讨会



研讨主持人
周鑫彦 博士
开心生活科技战略与创新副总裁



讨论嘉宾
刘建平 博士
北京中医药大学国际循证医学研究院执行院长，循证医学中心主任



讨论嘉宾
张雪 博士
北京中医药大学循证医学中心助理研究员，北京GRADE中心副主任



讨论嘉宾
李国强 博士
南京中医药大学公共卫生与预防医学学科带头人



讨论嘉宾
周林华 博士
中国中医科学院广安门医院代谢病研究所副所长



讨论嘉宾
李捷坤
中国中医科学院西苑医院临床药理研究所助理研究员

王会娟



张华



李庆娜-中国中医科学院西苑医院





业务进展

Business Progress

医渡科技旗下 HLT 助力首款国产 3CL 抗新冠创新药获批上市

HLT, a subsidiary of Yidu Tech, helped the first domestic 3CL anti-SARS-CoV-2 innovative drug to be approved to enter the market

首款具有自主知识产权的国产 3CL 抗新冠创新药先诺欣®获批上市，医渡科技旗下开心生活科技（HLT）提供 DCT 数字化解决方案，以患者为中心，帮助项目顺利开展，助力产品获批。

The first domestic 3CL anti-SARS-CoV-2 innovative drug with independent intellectual property rights, Xiannuoxin®, has been approved to enter the market. Happy Life Tech (HLT), a subsidiary of Yidu Tech, provided DCT digital solutions with a patient-centric approach to help the project run smoothly and facilitate the approval of the product.

2023 年度“江苏医惠保 1 号”获超 507 万人参保，医渡科技为主运营平台

Over 5.07 million people enrolled in 2023 Jiangsu Huimin Insurance with Yidu Tech as the main operating platform

1 月 31 日 24 时，2023 年度“江苏医惠保 1 号”投保顺利收官，总参保人数超过 507 万，参保规模超去年同期 200 万。放眼全国，参保人数也位居前列。医渡科技旗下医渡云为“江苏医惠保 1 号”主运营平台。医渡科技旗下因数云依托数据智能与医疗健康专业及优势，为“江苏医惠保 1 号”提供技术驱动的全流程运营服务。

At 24:00 on 31 January, the 2023 Jiangsu Huimin Insurance policy closed successfully, with a total of over 5.07 million participants, 2 million more than that of the same period last year. The number of participants was also among the highest in terms of Huimin Insurance products in China. YiduCloud, a subsidiary of Yidu Tech, undertaken the construction of main operating platform of Jiangsu Huimin Insurance. And CausaCloud, a subsidiary of Yidu Tech, provided technology-driven whole-process operation services for “Jiangsu Huimin Insurance” relying on data intelligence technology and medical expertise advantages.

医渡云签署宁波市第一医院临床科研数据库平台采购合同

YiduCloud signs procurement contract for clinical research database platform with Ningbo First Hospital

医渡科技公告，公司的联属公司医渡云（北京）技术有限公司与宁波市第一医院签署临床科研数据库平台采购合同。经授权后，凭借自主研发的「医疗智能大脑」YiduCore，公司将利用人工智能及大数据技术为客户提供全院数据治理及功能部署。该平台将实现全院不同维度的数据分析，亦可按照各科室需求自主创建科室数据库，提高研究级证据产出的效率，满足管理和研究需求，助力提升研究效率。

Yidu Tech announced that YiduCloud (Beijing) Technology Co., Ltd, an affiliate of the Company, signed a procurement contract with Ningbo First Hospital for clinical research database platform. With the authorization, the company will use artificial intelligence and big data technology to provide the customer with hospital-wide data governance and function deployment by virtue of its self-developed healthcare intelligence brain “YiduCore”. The platform will enable hospital-wide data analysis in different dimensions, and create departmental databases according to the needs of each department, improving the efficiency of research-level evidence output, meeting management and research needs, and helping to improve research efficiency.

医渡科技与某 MNC 签约 iSMO 服务，进一步深耕眼科领域

Yidu Tech signs iSMO service with a MNC to further develop the field of ophthalmology

某 MNC 发起一项评估 XEN45 青光眼治疗系统治疗中国开角型青光眼受试者的有效性和安全性的上市后研究，医渡科技为其提供 iSMO 服务。医渡科技基于数据智能优势，iSMO 业务得到快速发展，迄今已开展各类临床试验 180 多项，积累了丰富的临床试验经验与资源，未来将打通临床试验全链条，用数据智能赋能临床试验从业者，为行业发展提供智能动力。

A MNC initiated a post-marketing study to evaluate the effectiveness and safety of the XEN45 Glaucoma Treatment System in treating Chinese subjects with open-angle glaucoma, for which Yidu Tech provided iSMO services. Based on the

advantages of data intelligence, iSMO business of Yidu Tech has been developing rapidly. So far, Yidu Tech has conducted more than 180 iSMO projects and accumulated rich clinical trial experience and resources. In the future, it aims to open up the whole chain of clinical trials, empower clinical trial practitioners with data intelligence and provide intelligent power for the development of the industry.

医渡科技与某创新药企签约 iSMO 服务，助力干细胞研发

Yidu Tech signs iSMO service contract with an innovative pharmaceutical company to help stem cell R&D

某创新药企发起一项 hUC-MS C PLEB001 治疗激素失败急性移植物抗宿主病 (aGVHD) 的多中心、单臂关键性临床研究，医渡科技为其提供 iSMO 服务。本次签约因医渡科技旗下 HLT 获得客户好评而复购。

An innovative pharmaceutical company initiated a multi-centre, single-arm pivotal clinical study of hUC-MS C PLEB001 for the treatment of hormone failure acute graft-versus-host disease (aGVHD), for which Yidu Tech provided iSMO services. This contract was repurchased due to the positive customer feedback received by HLT, a subsidiary of Yidu Tech.

集团荣誉

Group Honor

医渡科技荣获 2022 年度 ESG 十大优秀企业奖

Yidu Tech awarded the 2022 ESG Top 10 Outstanding Enterprises Award

1 月 12 日，由华夏时报社主办的第二届华夏大健康™产业高峰论坛暨金手杖奖揭晓仪式顺利举行，医渡科技荣膺 2022 年度 ESG 十大优秀企业奖。医渡科技依托公司整体 ESG 战略和治理体系，在公共卫生管理、人口健康管理、新药研发、“惠民保”等场景中提供高效的医疗服务，积极创造社会价值。未来，医渡科技将继续坚定不移地践行“使价值导向的精准医疗惠及每一个人”的使命，以科技力量赋能医疗行业降本增效。

On January 12, the 2nd China Healthcare Industry Summit and Golden Cane Award Unveiling Ceremony, hosted by China Times, was successfully held. Yidu Tech was

awarded 2022 ESG Top 10 Outstanding Enterprises Award. Relying on the company's ESG strategy and governance structure, Yidu Tech provides efficient healthcare services in scenarios including public health management, population health management, new drug research and development, and Huimin Insurance, and actively creates social value. In the future, Yidu Tech will continue to steadfastly carry out its mission of bringing value-based precision healthcare to everyone, and empower the healthcare industry to reduce costs and increase efficiency with the power of technology.



技术创新驱动高质量发展，医渡科技连获多项资本市场殊荣

Technological innovation drives high-quality development, and Yidu Tech has won numerous capital market honors

由《21 世纪经济报道》主办的 2022 年资本市场「金帆」案例发布，医渡科技获评“2022 年度卓越科技价值上市公司”。与此同时，医渡科技荣登亿欧大健康“2022 中国大健康产业创新上市企业 TOP10”榜单，以及荣获第六届中国卓越 IR “最佳股东关系奖”。连获多项殊荣，体现医渡科技在科技创新、战略落地、市场成长空间等多方面的综合实力获得业界认可。

The "Golden Sail" case of the capital market in 2022, sponsored by the 21st Century Business Herald, was released, and Yidu Tech was awarded the "Outstanding Technology Value Listed Company in 2022". At the same time, Yidu Tech won the "2022 China Top 10 Innovative Listed Companies in Healthcare Industry" held by EqualOcean Health and the "Best Shareholder Relationship Award" of the 6th China Excellent IR. Yidu Tech has won numerous awards in succession, which reflects the company's comprehensive strength in scientific and technological innovation, strategic implementation, market growth potential and other aspects have been recognized by the industry.



医渡科技旗下医渡云荣膺海淀高价值专利培育大赛三等奖

YiduCloud, a subsidiary of Yidu Tech, wins third prize in Haidian District High Value Patent Cultivation Competition

2022 中国·海淀高价值专利培育大赛决赛暨颁奖典礼成功举办，医渡云携“医疗大健康领域知识图谱构建技术高价值专利培育”项目荣获大赛三等奖。据悉，大赛吸引来自全国近百个项目报名参赛，经过了海选、复赛环节的选拔，以及 12 个项目决赛角

逐，医渡科技此次获奖充分体现了公司在医疗智能领域核心技术研发、高价值专利培育方面的前瞻布局 and 实力。

The final of the 2022 China Haidian District High-Value Patent Cultivation Competition and the award ceremony were successfully held, and YiduCloud won the third prize for its project " *High-Value Patent Cultivation for Knowledge Graph Construction Technology in Medical Health Field* ". It is reported that the competition attracted nearly 100 projects from all over the country, and after the selection process and the semi-finals, as well as the final competition of 12 projects, this award fully reflected the forward-looking layout and strength of Yidu Tech in the research and development of core technologies and cultivation of high-value patents in the field of healthcare intelligence.

医渡科技旗下因数云荣登 2022 年度中国保险科技 100 强榜单

CausaCloud, a subsidiary of Yidu Tech, named in China Top 100 InsurTech Companies for 2022

知名保险科技交流平台分子实验室发布了 2022 年度中国保险科技 100 强名单。凭借在技术、保险领域的持续深耕和不断创新，医渡科技旗下因数云成功上榜。2022 年，在多地惠民保项目中，因数云都取得了不菲的成绩。截至目前，因数云已在 3 省 10 市提供医疗智能赋能的定制型惠民保险运营服务，囊括了中国三大直辖市北京、天津及重庆，累计服务了超 2000 万参保人群。

INSLAB, a leading insurance technology communication platform, has released its list of China Top 100 InsurTech Companies in 2022. With its continuous cultivation and innovation in the field of technology and insurance, CausaCloud, a subsidiary of Yidu Tech, successfully made the list. In 2022, CausaCloud has achieved remarkable results in multiple Huimin Insurance projects. Up to now, CausaCloud has provided healthcare intelligence-enabled customized Huimin Insurance operation services in 3 provinces and 10 cities, including the three major municipalities in China of Beijing, Tianjin and Chongqing, and has served a total of over 20 million people.

INSLAB Top 100 of China InsurTech in 2022



INSLAB
分子实验室

分子实验室2022年度

中国保险科技100强



投资者交流

Investor Communication

花旗维持医渡科技买入评级，目标价为 24 港元

Citi maintains Buy rating on Yidu Tech with a price target of HK\$24

医渡科技受邀参加花旗举办的医疗健康日活动，并在活动中分享了行业和公司的最新进展情况。花旗发布报告指出，YiduCore 积累的洞见和知识是医渡科技的核心竞争优势。

势，基于其生态系统及强大的网络效应，医渡科技业务将进一步发展扩大，维持医渡科技买入评级，目标价为 24 港元。

Yidu Tech was invited to participate in the Healthcare Day Event organized by Citi, where it shared the latest progress of the industry and the company. Citi released the research report stating that the insight and knowledge accumulated by YiduCore is one of the Yidu Tech's core competitive advantages. Based on its ecosystem and strong network effect, Yidu Tech's business will further develop and expand, therefore maintaining a Buy rating on Yidu Tech with a target price of HK\$24.